<DOC>
	<DOCNO>NCT01615042</DOCNO>
	<brief_summary>Lenalidomide drug alters immune system may also directly toxic tumor . Therefore , theory , may reduce prevent growth cancer cell directly kill . We study lenalidomide use decrease bone marrow blast cell preparation bone transplant .</brief_summary>
	<brief_title>Phase I Study Lenalidomide Patients With Acute Leukemia</brief_title>
	<detailed_description>We hypothesize lenalidomide high dos use decrease bone marrow blast count patient relapse refractory acute myeloid leukemia preparation allogeneic stem cell transplant acceptable toxicity worse current cytotoxic chemotherapeutic agent . The known dose-limiting toxicity 75 mg excessive fatigue previous phase I trial study may irrelevant study participant in-patient status .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Understand voluntarily sign informed consent form . Between 18 80 year age time sign informed consent form . Able adhere study visit schedule protocol requirement . NonM3 Acute Myeloid Leukemia presence residual disease bone marrow day 1428 post induction ( reinduction ) chemotherapy . Day 1428 residual disease define study presence 10 % blast marrow , presence 510 % blast cell cluster hypocellular marrow ambiguous bone marrow biopsy repeat 57 day . Patient already identify sibling , match unrelated donor cord blood donor time enrollment clinical trial . Eastern Cooperative Oncology Group ( ECOG ) performance status equal le 3 study entry ( patient population typically admitted hospital ) Laboratory test result within defined range Disease free malignancy beside acute myeloid leukemia ( AML ) great equal 2 year exception currently treat basal cell , squamous cell carcinoma skin , carcinoma `` situ '' cervix breast . All study participant must register mandatory RevAssist® program , willing able comply requirement RevAssist® . Females childbearing potential ( FCBP ) must negative serum urine pregnancy test sensitivity least 50 milliInternational unit ( mIU ) /mL within 10 14 day within 24 hour prior prescribe lenalidomide prescription must fill within 7 day require RevAssist ) must either commit continued abstinence heterosexual intercourse begin TWO acceptable method birth control , one highly effective method one additional effective method AT THE SAME TIME , least 28 day start take lenalidomide . FCBP must also agree ongoing pregnancy test . Men must agree use latex condom sexual contact FCBP even successful vasectomy . Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form . Pregnant breast feeding female ( Lactating female must agree breast feed take lenalidomide ) . Patients young 50 year old , first induction chemotherapy , able safely tolerate reinduction therapy high dose chemotherapy eligible study . Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study . Use experimental drug therapy within 14 day baseline . Known hypersensitivity thalidomide lenalidomide ( applicable ) . The development erythema nodosum characterize desquamate rash take thalidomide similar drug . Known seropositive active viral infection human immunodeficiency virus , hepatitis B virus hepatitis C virus . Patients seropositive hepatitis B virus vaccine eligible . Patients able swallow lenalidomide capsule whole exclude study . Patients impaired gastrointestinal absorption Symptomatic congestive heart failure Unstable angina pectoris cardiac arrhythmia History adrenal insufficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Acute Leukemia</keyword>
	<keyword>Bone Marrow Transplant</keyword>
	<keyword>High Dose Lenalidomide</keyword>
</DOC>